Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624137 · ClinicalTrials.gov registry record
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
A clinical trial of PTSD and Healthy Volunteer, sponsored by Yale University.
- Recruiting
- Registry status
- 200
- Enrollment target
- 2
- Study locations
NCT06624137: Recruiting study of PTSD and Healthy Volunteer, sponsored by Yale University.
NCT06624137 is a study of PTSD and Healthy Volunteer that is actively recruiting participants, run by Yale University. The registered enrollment target is 200 participants, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (34% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06624137, a study of PTSD and Healthy Volunteer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are: 1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use? 2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs? 3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect? 4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics? Researchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics. Participants will have the opportunity to do some combination of the following: 1. Online computer assessments consisting of games and questionnaires that probe how participants think. 2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered. 3. A magnetic resonance imaging (MRI) scan. 4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.
Primary Outcome
Participants' trial-by-trial responses on auditory and visual conditioned hallucination (CH) tasks as well as a probabilistic reversal learning (PRL) task are fitted with an enhanced Hierarchial Gaussian Filter (eHGF) model of hierarchial belief updating under perceptual/informational uncertainty using eHGF package in Julia. Precision weighted prediction errors used to update the 2nd and 3rd levels are estimated for each trial for each individual. Average precision weighted prediction errors acr
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Serotonergic Psychedelic
Study Locations (2)
Connecticut
- Connecticut Mental Health Center - Hamden
- West Haven VA Medical Center - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2028-05 |
What NCT06624137 shows while recruiting
NCT06624137 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 301-participant average among 154 other PTSD trials with a reported enrollment target (34% lower).
The record links to 10 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06624137 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06624137 about?
NCT06624137 is a clinical study titled "Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics". The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine/DMT, Lystergic Acid Diethylamide/LSD, etc.) for people with and without mental illness receiving seroto...
What is the current status of trial NCT06624137?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-12-12. Estimated completion is 2028-05.
What conditions does trial NCT06624137 study?
This clinical trial studies the following conditions: PTSD, Healthy Volunteer, Migraine, Tobacco Use Disorder, Alcohol Use Disorder (AUD).
What interventions are being tested in trial NCT06624137?
The interventions under investigation include: Placebo (DRUG), Serotonergic Psychedelic (DRUG).
Who is sponsoring clinical trial NCT06624137?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624137 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06624137's enrollment target sits among peer trials
200 28th of 154 higher than 126 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
-
REstoring Mental Health Through COmmUnity-based Psychological Services in New York City
RECRUITING · NA
-
Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RECRUITING · NA
-
Project Safe Guard-Trauma
RECRUITING · NA
-
Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI